Immunic (IMUX) Expected to Announce Earnings on Thursday

Immunic (NASDAQ:IMUX) is expected to issue its quarterly earnings data before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.22) per share for the quarter.

Immunic Trading Down 4.2 %

Shares of NASDAQ IMUX opened at $1.15 on Wednesday. The firm has a market capitalization of $103.59 million, a PE ratio of -0.93 and a beta of 1.87. The firm’s 50-day moving average is $1.03 and its 200-day moving average is $1.25. Immunic has a 1 year low of $0.92 and a 1 year high of $2.11.

Analyst Ratings Changes

A number of research analysts have recently weighed in on IMUX shares. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Immunic in a research note on Friday, February 21st. D. Boral Capital reissued a “buy” rating and issued a $17.00 target price on shares of Immunic in a research note on Thursday, February 20th. Finally, StockNews.com cut Immunic from a “hold” rating to a “sell” rating in a research note on Saturday. One investment analyst has rated the stock with a sell rating, six have given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Immunic has an average rating of “Buy” and a consensus target price of $12.67.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.